Prosecution Insights
Last updated: November 12, 2026

Ultragenyx Pharmaceutical Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days

Analysis

Ultragenyx Pharmaceutical Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 3 art units, indicating separate examination assignments.

BENAVIDES, JENNIFER ANN is the busiest examiner, with 1 pending matter. Counsel should coordinate the technical record across the matters while preparing responses tailored to each examiner and art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
2
Medium (67%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (33%)
Double-patenting + other1 (33%)
Multi-statute (no §101)1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BENAVIDES, JENNIFER ANN 1 50.8% +48.2%
MOORE, JOHN DAVID 1 61.1% +28.3%
SIFFORD, JEFFREY MARK 1 54.4% +33.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18683819 ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES SIFFORD, JEFFREY MARK —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18696578 METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTA BENAVIDES, JENNIFER ANN —
18684333 RECOMBINANT AAV FORMULATIONS MOORE, JOHN DAVID —
18683819 ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES SIFFORD, JEFFREY MARK —

Top Art Units

Art UnitApps
1675 1
1638 1
1671 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18696578 METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTA BENAVIDES, JENNIFER ANN 1675 §102§112DP Non-Final OA — Pending Mar 28, 2024
18684333 RECOMBINANT AAV FORMULATIONS MOORE, JOHN DAVID 1638 §103 Final Rejection — Pending Feb 16, 2024
18683819 ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES SIFFORD, JEFFREY MARK 1671 §103§112 Final Rejection — Pending Feb 15, 2024

Managing Ultragenyx Pharmaceutical Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ultragenyx Pharmaceutical Inc. have?

Ultragenyx Pharmaceutical Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Ultragenyx Pharmaceutical Inc. applications?

Jennifer Ann Benavides has the most, with 1 of Ultragenyx Pharmaceutical Inc.'s pending office actions.

What technology area are Ultragenyx Pharmaceutical Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month